Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc.

RLMD·NASDAQ

$6.38

-0.62%
HealthcareBiotechnology

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

At a Glance

Live Snapshot
Market Cap$467.87M
EPS-1.4500
P/E Ratio-4.40
Earnings Date08/06/2026

rlmd

Net Common Stock Issuance

Last Annual Value

93.64M

3-Year CAGR

30%

5-Year CAGR

35%

10-Year CAGR

%

Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc. Competitors Analysis of Net Common Stock Issuance

RLMD · NASDAQ
CompanyNet Common Stock Issuance
CAGR 3Y
CAGR 5Y
CAGR 10Y
93.64M
N/A-12.8%N/A 
264.00K
-81.6%-68.8%N/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
75.50M
480.5%-20.5%N/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
4.44M
-33.4%-48.5%N/A
61.17M
N/AN/AN/A
CLNN logo
Clene Inc.
NASDAQ:CLNN
10.40M
-37.2%2.4%N/A
6.03M
-31.0%-44.2%N/A
371.00K
N/AN/AN/A
95.16M
167.2%9.5%113.2%
25.04M
-43.1%-31.1%N/A
376.00K
-68.4%N/AN/A
Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc. Fair Value Envelope

RLMD · NASDAQ

Our analysis suggests that RLMD has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $6.38, this represents a potential HIDDEN relative to our calculated worth for Relmada Therapeutics, Inc..

Intrinsic Value
Current Price: $6.38